| Stereochemistry | ABSOLUTE |
| Molecular Formula | C8H15N2O5P |
| Molecular Weight | 250.1889 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)[C@H]1CN(C\C=C\P(O)(O)=O)CCN1
InChI
InChIKey=VZXMZMJSGLFKQI-ABVWVHJUSA-N
InChI=1S/C8H15N2O5P/c11-8(12)7-6-10(4-2-9-7)3-1-5-16(13,14)15/h1,5,7,9H,2-4,6H2,(H,11,12)(H2,13,14,15)/b5-1+/t7-/m1/s1
| Molecular Formula | C8H15N2O5P |
| Molecular Weight | 250.1889 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
Midafotel (CPPene; SDZ EAA 494) is a selective competitive antagonist at the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor. It was originally designed as a potential therapy for excitotoxicity, epilepsy or neuropathic pain. Midafotel had been in phase III clinical trials by Novartis for the treatment of brain injury. However, this research has been discontinued.
CNS Activity
Originator
Approval Year
Doses
Sourcing
PubMed
Patents
Sample Use Guides
Midafotel was administered either as single doses at a dose range of 1-50 mg, or as multiple doses over the course of 1 week at doses of 25 mg once or twice daily.
Route of Administration:
Oral
Midafotel (d-CPPene) strongly inhibited the frequency of spontaneous
epileptiform discharges. This effect was concentration-dependent.
Epileptiform discharges were reduced up to 70% at a concentration of 0.1 uM and were completely blocked at a concentration of 0.3 uM in the rat cortical wedge preparation. d-CPPene inhibited in concentration-dependent manner
NMDA-induced depolarisations. A concentration of 0.1 uM
that blocked 70% of spontaneous discharges inhibited 60%
of depolarisations induced by NMDA. A concentration of
1 uM completely blocked NMDA-induced depolarisations.
